查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1468354

2024-2032年依類型（鹽酸多柔比星、舒尼替尼、多西他賽、絲裂黴素、氟尿嘧啶、伊馬替尼、曲妥珠單抗）、給藥途徑（口服、腸胃外）、最終用戶（醫院、診所等）和地區的胃癌藥物市場報告

Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球胃癌藥物市場規模達46億美元。慢性和急性適應症盛行率的上升、與體重相關的健康問題的發生率不斷上升以及健康意識的增強是推動市場發展的一些關鍵因素。

胃癌藥物是為了緩解或治療被診斷出患有胃癌（胃內壁形成惡性細胞）的患者而開發的藥物。胃癌的一些常見症狀是不明原因的體重減輕、消化不良、腹脹、噁心、嘔吐、胃灼熱和吞嚥食物困難。鹽酸阿黴素、舒尼替尼、絲裂黴素、氟尿嘧啶、伊馬替尼和多西他賽是常用的胃癌藥物。它們透過殺死一些癌細胞來幫助縮小腫瘤並緩解癌症的跡象和症狀。它們還有助於減少癌細胞的生長、分裂和產生更多細胞。因此，胃癌藥物透過口服和腸胃外形式給藥，並由醫院、診所和特殊治療中心使用。

全球老年人口的增加和肥胖症的盛行率上升主要推動了市場的成長。與此一致的是，由於不健康的飲食習慣和久坐的生活方式，與體重相關的健康問題的發生率不斷增加，有利於市場的成長。此外，由於菸草製品和酒精飲料的消費增加，癌症病例不斷增加，以及對預防和治療藥物的需求增加，是另一個促進生長的因素。除此之外，兩種有助於消除腫瘤生長的胃癌生物標記的推出也為市場成長提供了動力。此外，製造商正專注於創造副作用最小的產品變體，例如胃糜爛和噁心，從而推動市場成長。同時，專注於開發有效和特異性癌症治療方法的快速技術進步正在為市場創造積極的前景。此外，領先的製藥公司和主要參與者正在大力投資研發 (R&D) 活動，以開發更安全、更有效、經濟上可行且更易於管理的胃癌藥物。除此之外，政府實施各種促進藥品製造、加工和包裝的舉措，確保製造商生產的藥品質量，對市場成長有正面影響。其他因素，包括醫療保健支出的增加以及消費者對胃癌症狀和可用治療方案的認知不斷增強，預計將推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球胃癌藥物市場表現如何，未來幾年將如何表現？
  • 全球胃癌藥物市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的胃癌藥物市場？
  • 依類型分類市場是怎麼樣的？
  • 根據給藥途徑，市場的分化為何？
  • 基於最終用戶的市場區隔是什麼？
  • 全球胃癌藥物市場競爭格局如何？
  • 全球胃癌藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球胃癌藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按類型

  • 鹽酸阿黴素
    • 市場走向
    • 市場預測
  • 舒尼替尼
    • 市場走向
    • 市場預測
  • 多西紫杉醇
    • 市場走向
    • 市場預測
  • 絲裂黴素
    • 市場走向
    • 市場預測
  • 氟尿嘧啶
    • 市場走向
    • 市場預測
  • 伊馬替尼
    • 市場走向
    • 市場預測
  • 曲妥珠單抗
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依管理途徑

  • 口服
    • 市場走向
    • 市場預測
  • 注射用
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 診所
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Arog Pharamaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and company
    • F. Hoffmann-La Roche AG
    • Ono Pharmaceutical Co. Ltd.
    • Sanofi SA
    • Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
Product Code: SR112024A6648

The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.26% during 2024-2032. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.

Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.

The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, and end user.

Type Insights

Doxorubicin Hydrochloride

Sunitinib

Docetaxel

Mitomycin

Fluorouracil

Imatinib

Trastuzumab

The report has provided a detailed breakup and analysis of the gastric cancer drugs market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest segment.

Route of Administration Insights

Oral

Parenteral

A detailed breakup and analysis of the gastric cancer drugs market based on the route of administration has also been provided in the report. This includes oral and parenteral. According to the report, parenteral accounted for the largest market share.

End User Insights

Hospitals

Clinics

Others

The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.

Regional Insights

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive gastric cancer drugs market?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on end user?
  • What is the competitive structure of the global gastric cancer drugs market?
  • Who are the key players/companies in the global gastric cancer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastric Cancer Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Doxorubicin Hydrochloride
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sunitinib
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Docetaxel
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mitomycin
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fluorouracil
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Imatinib
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Trastuzumab
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arog Pharamaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Daiichi Sankyo Company Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ono Pharmaceutical Co. Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi S.A.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List of Figures

  • Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure
  • Table 7: Global: Gastric Cancer Drugs Market: Key Players